



Communicating Research Results

- Mario R. Festin MD, MS, MHPed, FPOGS, FPCS
- College of Medicine – Philippine General Hospital
- University of the Philippines Manila

Purpose

- *Guidelines and techniques in communicating research results through*
 - *the scientific research abstract and*
 - *poster presentation*
- within a well-organized scientific framework.*

Outline of Presentation

- State of the Art of Publication in the Philippines
- Sources of guides for scientific paper writing
- Guides for Making a Structured Abstract
- Guides for Making a Scientific Poster

Scientific Research Activities

- POGS receives
 - 75-90 interesting case papers each year
 - 50-60 research papers per year
 - 20-26 interesting case papers from PGH
 - 12-16 research papers from PGH
- Only top 3 IC papers and 3 Research Papers get published in the PJOG
- Maybe 1-2 get published in the Acta Medica Philippina
- **NO PAPER GETS PUBLISHED IN THE INTERNATIONAL JOURNALS**

Scientific writing

Scientific Paper

- Scientific paper writing skills need to be formally taught.

- Formal courses

- DCE – beginning 2nd semester 2005-6
- CPH – DEBS – starting this year

- Informal Courses

- PCS – writing
- POGS – writing and editing

- Needs a seasoned person to assist in the writing of the paper

- Report read in the department or staff conference is NOT the format for the paper writing

- Standard formats have been described (ICMJE)

- Need to institutionalize the **CONSENT BY AUTHORS FOR PUBLICATION**

Scientific Research Paper

- First publication of original result
- Contains sufficient information to enable peers to assess observations, repeat experiments and evaluate intellectual processes
- In a journal or other resource readily available to the scientific community (including the web)
- PROBLEM IN THE PHILIPPINES – TOO MANY JOURNALS ATTEMPT TO PUBLISH
 - Every new medical society or college or department – first project = journal

Standards for Medical Publishing

□ International Committee of Medical Journal Editors

ICMJE

□ Committee of Publication Ethics – Code of Conduct for Editors of Biomedical Journals

A code of conduct for editors of biomedical journals

A suggested code of conduct for editors to guide them towards being fair to authors, researchers, and readers)



Preamble

Editors of biomedical journals should be responsible for everything published in their journals. They should strive to meet the needs of readers and authors; constantly improve the journal; ensure the quality of the material they publish; champion freedom of expression in science and health care; maintain the integrity of the scientific record; preclude business needs from compromising intellectual standards; and always be willing to publish corrections, clarifications, retractions, and apologies when needed.

Any deviation from this code of conduct could be misconduct and should be pursued in the first instance through the journal's complaints procedure. If the matter is unresolved, a complaint may be referred to COPE. (The process for dealing with complaints against editors referred to COPE is described below.)

Quality and correcting the record

Editors should take all reasonable steps to ensure the quality of the material they publish, recognising that journals and sections within journals will have different aims and standards.

Descriptions of peer review processes should be published, and editors should be ready to justify any important deviation from the described processes. Journals should have a declared mechanism for authors to appeal against editorial decisions.

Whenever it is recognised that a significant inaccuracy, misleading statement or distorted report has been published, it must be corrected promptly

Full Screen



menue.

An apology must be published whenever appropriate.

Close Full Screen

If after an appropriate investigation articles prove to be fraudulent or contain major errors that are not apparent from the text, the articles should be retracted. The word retraction should be used in the title of the retraction to ensure that it is picked up by indexing systems.

ICMJE GUIDES

IV. Manuscript Preparation and Submission

A. Preparing a Manuscript for Submission to Biomedical Journals

1. General Principles and Reporting Guidelines
 - a. General Principles
 - b. Reporting Guidelines for Specific Study Designs
2. Title page
3. Conflict of Interest Notification Page
4. Abstract and Key Words
5. Introduction
6. Methods
 - a. Selection and Description of Participants
 - b. Technical Information
 - c. Statistics
7. Results
8. Discussion
9. References
 - a. General Considerations Related to References
 - b. Reference Style and Format
10. Tables
11. Illustrations (Figures)
12. Legends for Illustrations (Figures)
13. Units of Measurement
14. Abbreviations and Symbols

B. Sending the Manuscript to the Journal

V. References

A. Print References Cited in this Document

B. Other Sources of Information Related to Biomedical Journals

What to do before submission

First submissions to *The Lancet*:

- Covering letter
- Manuscript — two copies double-spaced with word count for text alone on front page
- Figures — two sets
- Authors' contributions and signatures
- Conflict of interest and source of funding
- Patients' consent and permission to publish
- In-press papers — one copy of each with acceptance letters
- Acknowledgments — include written consent of cited individual
- Personal communications — include written consent of cited individual
- Protocols and CONSORT details for randomised controlled trials
- We encourage disclosure of correspondence from other journals and reviewers, if previously submitted, and we might contact relevant editors of such journals
- Use of copyright-protected material — signed permission statements from author and publisher needed

<http://journals.elsevierhealth.com/periodicals/ymob>

ELSEVIER

AMERICAN JOURNAL of OBSTETRICS and GYNECOLOGY

[Register](#) or Login: Password: [SIGN IN](#) Auto-Login [Reminder](#)

Search for [GO](#)

[Advanced Search](#) - [MEDLINE](#) - [My Recent Searches](#) - [My Saved Searches](#) - [Search Tips](#)

- ▶ [AJOG HOME](#)
- [CURRENT ISSUE](#)
- [BROWSE ALL ISSUES](#)
- [SEARCH THIS JOURNAL](#)
- [AJOG SUPPLEMENTS](#)
- [ONLINE EXCLUSIVES](#)
- [EDITOR'S CHOICE](#)
- [JOURNAL INFORMATION](#)
 - [Aims and Scope](#)
 - [Editorial Board](#)
 - [Author Information](#)
 - [Permission to Reuse](#)
 - [Info for Advertisers](#)
 - [Contact Information](#)
 - [Society Information](#)
 - [Pricing Information](#)
- [SUBSCRIBE TO AJOG](#)
- [SEARCH FOR JOBS](#)
- [FREE TRIAL ISSUE](#)
- [MY PDA](#)



Current Issue

[August 2005](#) | [Vol. 193, No. 2](#)

[VIEW CURRENT ISSUE](#)

[VIEW ALL ISSUES](#)

[SEARCH THIS JOURNAL](#)

[SUBMIT MANUSCRIPT](#)

[ACTIVATE ONLINE ACCESS](#)

Welcome to the New *American Journal of Obstetrics and Gynecology* Online

The site now contains additional features and a new look-and-feel. Full-text articles are available to personal subscribers starting from 1994 through the present. Access to abstracts is complimentary. [Click here for additional information.](#)

Already have a username and password? [Click here to log in.](#)

First-time User? [Create an account here.](#)

Institutional subscribers:
[Click here to access your journal subscription](#)

ABOUT AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

American Journal of Obstetrics and Gynecology, "The Gray Journal," presents coverage of the entire spectrum of the field, from the newest diagnostic procedures to leading-edge research. The Journal provides comprehensive coverage of the specialty, including maternal-fetal medicine, reproductive endocrinology/infertility, and gynecologic oncology. It also publishes the annual meeting program.

Subscribe to the journal now!



Internet



PREPARING THE STRUCTURED ABSTRACT

- Based on ICJME guidelines
- EJ Huth, Writing and Publishing in Medical Sciences
- Iles RL, Guide to Better Medical Writing
- Hall GM, How to Write a Paper

Sample Abstract

Advances in ___ have allowed physicians to be more aggressive in the management of _____. Sometimes this change is dependent on the willingness on our part to look at these so-called techniques with an open mind rather than through incredulous eyes. When adopted in mentality and practice, these advances have led to better outcomes and more meaningful survival for our patients.

.....

This new model of treatment requires that specialists stay abreast of developments not only on his particular field but also in one another's. For instance it is valuable for a specialist to know the latest trends in _____ management as it affects surgical decision-making and in order to participate in the multi-disciplinary process.

Comments

- ❑ Too non-specific
- ❑ Vague??
- ❑ Looks like a generic template, with fill in the blanks
- ❑ Not reflective of what will be presented in the paper
- ❑ Gives an impression that the author has not prepared the full paper yet.

IV.A.4. Abstract and Key Words

An abstract (requirements for length and structured format vary by journal) should follow the title page. The abstract should provide the context or background for the study and should state the study's purposes, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations.

Because abstracts are the only substantive portion of

The Abstract

- This serves as a miniaturized study report.
- The TITLE and the ABSTRACT will be read by more people than any other part of the paper.
- Usually follows the structured format and the non-structured format.
- The STRUCTURED ABSTRACT will reveal key features in the study, that will help readers determine if they want to read the whole paper.

■ Iles RL, Guide to Better Medical Writing, 1997

TYPES OF ABSTRACTS

□ INFORMATIVE ABSTRACTS

- Summarizes what the paper actually says.
- Each section/ heading should have at least one sentence, if using the structured format

□ INDICATIVE ABSTRACTS

- Simply indicates what the paper is about and does not summarize what it says.
- Used for articles or reviews that contain a large amount of detail that is not readily boiled to a few main points.

■ Huth EJ, Writing and Publishing in Medicine, 3rd ed. 1999

Key Information in Structured Abstracts

- OBJECTIVE – exact question addressed
- DESIGN – basic one used in the paper
- SETTING – location and level of care
- PATIENTS OR PARTICIPANTS – includes the manner of selection, numbers of participants who entered and completed the study.
- INTERVENTION – or treatment
- MEASUREMENTS OR RESULTS – methods
- CONCLUSIONS – may include clinical applications
 - Ann Int Med 1987 106: 598-604

IMRAD

- Introduction, Methods, Results, and Discussion, + Recommendation
- Authors need to coordinate closely with editors in using such required publication formats and should submit material for potential supplementary electronic formats for peer review.
- **DOUBLE SPACE ALL PAGES INCLUDING TABLES, REFERENCES, LEGENDS**

Some journals request that, following the abstract, authors provide, and identify as such, 3 to 10 key words or short phrases that capture the main topics of the article. These will assist indexers in cross-indexing the article and may be published with the abstract. Terms from the Medical Subject Headings (MeSH) list of Index Medicus should be used; if suitable MeSH terms are not yet available for recently introduced terms, present terms may be used.



A service of the National Library of Medicine and the National Institutes of Health

My NCBI [Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search MeSH for [] Go Clear

- GSS
- EST
- Structure
- Genome
- Books
- CancerChromosomes
- Conserved Domains
- 3D Domains
- Gene
- Genome Project
- GENSAT
- GEO Profiles
- GEO DataSets
- HomoloGene
- Journals
- MeSH
- NCBI Web Site
- NLM Catalog
- OMIA
- OMIM
- PMC
- PopSet
- Probe
- PubChem BioAssay
- PubChem Compound
- PubChem Substance
- SNP
- Taxonomy
- UniGene
- UniSTS

Preview/Index History Clipboard Details

get started, enter one or more search terms.
Search terms may be [topics](#), [authors](#) or [journals](#).

XML **RSS** **News flash: deliver PubMed search results directly to your desktop with an RSS feed.**

up an [RSS feed](#):
in your search in PubMed.
lect *RSS Feed* from the *Send to* menu.
ck *Create Feed* and copy the XML icon into your RSS Reader.
ne [PubMed Help](#) to explore other options for automatic e-mail updates using My

MESH TERMS

a service of the [National Library of Medicine](#) that includes over 15
tions from MEDLINE and other life science journals for biomedical
ck to the 1950s. PubMed includes links to full text articles and other
ources.

International survey on variations in practice of the management of the third stage of labour

Mario R. Festin,¹ Pisake Lumbiganon,² Jorge E. Tolosa,³ Kathryn A. Finney,⁴ Katherine Ba-Thike,⁵ Tsungai Chipato,⁶ Hernando Gaitán,⁷ Liangzhi Xu,⁸ Sompop Limpongsanurak,⁹ Suneeta Mittal,¹⁰ Abraham Peedicayil,¹¹ Noor Pramono,¹² Manorama Purwar,¹³ Sheela Shenoy,¹⁴ & Sean Daly¹⁵

Objective To determine the use of the active management of the third stage of labour in 15 university-based obstetric centres in ten developing and developed countries and to determine whether evidence-based practices were being used.

Methods From March 1999 to December 1999, the Global Network for Perinatal and Reproductive Health (GNPRH) conducted an observational, cross-sectional survey to assess the use of the practice and its components. Prospective data on patient characteristics and the interventions used in the management of the third stage of labour were collected using standardized methods. Data on approximately 30 consecutive vaginal deliveries in each centre (452 in total) were included.

Findings Significant intracountry and intercountry variation in the practice of the active management of the third stage of labour was found (111/452 deliveries used active management), which confirmed the existence of a large gap between knowledge and practice.

Conclusion Areas identified for improvement are the urgent implementation of the evidence-based clinical management practice defined as the active management of the third stage of labour; increased accessibility to systematic reviews in developing countries; and the conduction of clinical trials that assess the impact of this intervention in other settings.

Keywords Labor stage, Third/drug effects; Postpartum hemorrhage/drug therapy; Oxytocin/therapeutic use; Umbilical cord; Delivery, Obstetric/methods; Hospitals, University; Evidence-based medicine; Cross-sectional studies; Multicenter studies; Developed countries; Developing countries (*source: MeSH, NLM*).

Indicative Abstract - Sample

This review covers the many different adverse effects that have been reported for the drugs most widely used in the treatment of breast cancer. It considers them as generalized systemic effects and by body systems. An attempt has been made to assess their life-threatening security and to suggest how patients can be monitored for their early detection.

Huth EJ, Writing and Publishing in Medicine, 3rd ed. 1999

TIPS for writing abstracts

- Ideally, write the abstract after the full paper has been written.
- In the first sentence/section, describe the STUDY DESIGN (question investigated and how)
- Do not repeat information that is in the title.
- List the more important results, using sentence fragments where appropriate to save space.
 - EX. Major findings: Fewer seizures (1.1/day vs. 5.2/day, $p < 0.02$), more undisturbed sleep (median 6 hr vs 3 hr, $p < 0.001$)
- Names of statistical tests need not be noted
- Do not put information in abstract that is not in the main paper.
 - Iles RL, Guide to Better Medical Writing, 1997

Abstract Submission

- ❑ ABSTRACTS WHEN SUBMITTED ARE RARELY EDITED AND TYPESET. (Camera-ready).
- ❑ Type within the prescribed area.
- ❑ Appropriate size typeface/font, and printed by high quality laser printer
- ❑ Errors in SPELLING, GRAMMAR, OR SCIENTIFIC FACT will be reproduced exactly as you type them.
- ❑ Look at the abstract instruction for SUBJECT CATEGORIES, and for venue, oral/poster.
 - Hall GM, How to Write a Paper, 3rd Ed. BMJ Books 2003

The checklist and copyright statement forms must be completed and submitted with the manuscript. The forms may be printed in another format as required, the information will not be considered. An explanation of the requirements is given in the information for authors.

- Covered**
 - Manuscript has been submitted under a binding copyright agreement for print reproduction including an electronic hard copy of the manuscript
 - The word count is _____ which includes abstract, text and references
 - The completed checklist and copyright statement signed by ALL authors
 - The final version is stored in Internet and made available upon request
 - Institution Review Board (IRB) _____ was obtained on _____ (date)
 - Gold return for research use of an article supported by donations or grants has been obtained in accordance with institutional policies. The grant is mentioned in the title, abstract, key words and Materials and Methods section
 - Total research type (check one)
 - Basic research as revealed in a CONSORT statement has been completed
 - Other analysis and synthesis or review of published or available data with CONSORT statement has been completed
 - Other paper
 - Case report
 - Analysis of data from a prospective or retrospective study
 - The cover letter with the manuscript is stored in the most appropriate folder: Authorship, Copyright, Previous Publications, and IRB approval
 - All elements of the manuscript are approved in the title, abstract, key words, introduction, objectives, methods, results, discussion, conclusion, key words, references, figures, and tables
 - All pages are numbered in the following order: title page, cover sheet, abstract, body of text, acknowledgements of those who have made contributions to the study, references, key words, and tables
 - Signed, written permission to use the copyright held by the author of tables, figures, or text is a prerequisite for publication and complete information is provided with the manuscript
 - Signed, written permission for the use of quotations of personal communications and unpublished data has been obtained from the person(s) being quoted

- Authorship**
 - In the cover letter, there is an acknowledgment of all authors (if filled) back cover sheet required for authorship
 - The following authors are government employees (has exempt from the copyright statement)

- Conflict of interest**
 - If an author has followed up, please list in the cover letter
 - Are any author's interests or those of employees of contributors in a company with products discussed in the article?
 - Do any author's interests or those of employees of a company whose products are discussed in this article (list the nature of such interests) exist in a company or business?
 - Are any author's interests or those of employees of a company whose products are discussed in this article

- Print and publications**
 - Copyright of previous print and electronic versions is a desired aspect of each paper has been checked

- References**
 - Names, address, phone and fax number and e-mail address of all authors have suggested references are included

- Title page**
 - The following elements are given in the following sequence:
 - Title, author(s), name(s) and full name, academic degrees, city(s), state(s), and country(ies) where the author(s) lives in which the study was conducted
 - Name(s) of institution(s) and city(s), department(s) in which the study was published and the institutional affiliation(s) of the author(s) at the time of the study
 - Address(es) of the author(s)
 - Names, address, phone and fax number and e-mail address of all authors and e-mail address of all members for members and e-mail address for non-members (if any)
 - If applicable, state if available, this is a letter to the editor, title page, or if the corresponding author is different from the author(s) who corresponds to the manuscript, list the name, address, phone and fax number of the members, for members, and e-mail address for non-members

- Cover sheet**
 - A single cover sheet no more than 25 words of text for the essential points (Abstract and key words or short phrases)
 - The abstract is printed on page 2 headed by the title and author(s) name(s). The word count must be 1 to 2 key words or short phrases are typical
 - A minimum abstract, not to 200 words or less, for regular research articles and not key regular research articles. The abstract is not for a required major headings (Hypothesis), Study Design, Results, and Conclusion(s), each with a list of key words or phrases
 - A maximum abstract is required for Clinical Update and AGS Reviews articles not to 700 words and for the Case Report and Brief Communication articles with a maximum of 700 words

- References**
 - Are all references current (only in the last 5 years are cited)
 - The format for the 73rd volume Supplement to the Journal of Stroke and Cerebrovascular Disease is used
 - Presence of references has been confirmed on published abstracts on our computerized reference list or manual list in the last 5 years, approved if the process being updated. The signed copy will be included

- Figures**
 - Each is numbered with an Author number and it will be a numeric sequence in the text
 - Signatures do not appear on the figures
 - Consistency in style has been established
 - Copyright for figures has been signed figure requirements may be found in the Information for authors

- Figure Legend**
 - Are printed for each figure and are numbered and appear in correct order
 - Consistent with the style of journal
- Tables**
 - Each table is headed by a title and is numbered in Roman numerals and are placed in correct sequence in the text

COPYRIGHT STATEMENT

Must be signed by ALL authors, upon submission

Copyright statement: "The copyright in this article is reserved by the manuscript publisher and the author(s)."

.....

in the event the work is published. The copyright in this article is reserved by the manuscript publisher and the author(s). This restriction shall not apply to abstracts or papers published in connection with the abstracting services. The author(s) shall retain the final manuscript in its original and electronic form but has been approved by the appropriate author.

The copyright in this article is reserved by the manuscript publisher and the author(s). (Print name)

..... (signature)

Each author's name must be printed on the back of the signature

.....

DATE:

CONSENT BY AUTHORS FOR PUBLICATION Ex. AJOG

Cover Letter for Each Manuscript

Manuscripts must be accompanied by a cover letter, which should include the following information.

- A full statement to the editor about all submissions and previous reports that might be regarded as redundant publication of the same or very similar work. Any such work should be referred to specifically, and referenced in the new paper. Copies of such material should be included with the submitted paper, to help the editor decide how to handle the matter.
- A statement of financial or other relationships that might lead to a conflict of interest, if that information is not included in the manuscript itself or in an authors' form
- A statement that the manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work, if that information is not provided in another form (see below); and
- The name, address, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs, if that information is not included on the manuscript itself.

The Review Process

- The journal will acknowledge the receipt of the paper. This does not mean it will be published.
- They will respond to you whether the paper will be reviewed by the journal or not.
 - The paper's content may not be aligned with the agenda or niche of the journal.
- Once informed for review, await the response. May need to follow up if no response.
- ONCE REVIEWERS RESPOND, ANSWER THE COMMENTS OR QUERIES UPON RESUBMISSION.

Journal Impact Factors

- Journal Impact Factor is from Journal Citation Report (JCR), a product of Thomson ISI (Institute for Scientific Information).
- JCR provides quantitative tools for evaluating journals.
- The impact factor is one of these; it is a measure of the frequency with which the "average article" in a journal has been cited in a given period of time.

Journal Impact Factors

□ The impact factor for a journal is calculated based on a three-year period, and can be considered to be the average number of times published papers are cited up to two years after publication. For example, the 2006 impact factor for a journal would be calculated as follows:

A = the number of times articles published in 2004-5 were cited in indexed journals during 2006

B = the number of articles, reviews, proceedings or notes published in 2004-5

$$2006 \text{ impact factor} = A/B$$


(note that the 2006 impact factor was actually published in 2007, because it could not be calculated until all of the 2007 publications had been received.)

2003 SCIENCE CITATION INDEX RANKING*

(Category: Obstetrics & Gynecology; Total field= 53 journals)

JOURNAL IMPACT FACTOR

	<u>2003</u>	<u>2002</u>	<u>2001</u>	<u>2000</u>
Human Reproduction Update	3.731	3.710	2.969	2.887
Fertility and Sterility	3.483	3.202	2.960	2.854
Menopause	3.319	3.217	3.305	2.273
Human Reproduction	3.125	3.253	2.987	2.997
Obstetrics & Gynecology	2.957	2.482	2.196	2.091
Placenta	2.706	2.359	2.521	2.587
Am J Obstetrics & Gynecology	2.518	2.556	2.871	2.519
Gynecologic Oncology	2.431	2.115	2.200	1.972
J of the Soc for Gyn Investigation	2.291	2.440	2.830	2.184
Intl J of Gynecologic Pathology	2.159	1.848	1.454	1.508
Maturitas	2.045	2.068	1.640	1.402





SCIENTIFIC POSTER PRESENTATION

- What it is.
- Parts
- Tips

THE POSTER

- A poster is simply a static, visual medium (usually of the paper and board variety) that you use to communicate ideas and messages.
- The difference between **poster** and **oral** presentations is that you should let your poster do most of the 'talking'; that is, the material presented should convey the essence of your message.
- A POSTER EXHIBIT IS NOT A JOURNAL ARTICLE, and people do not have time to read long text. Use outlines with bullets.

THE POSTER

- You have to 'stand-by-your-poster'!
- Your task as the presenter is to answer questions and provide further details; to bask in praises or suffer difficult questions; and to convince others that what you have done is excellent and worthwhile.

3 Incarcerated uterine prolapse with massive eversion of the vagina: A case report
Myrene David-Umpig, MD, Nephthali Gorgonio, MD, Ma Cristina Fabella, MD
Amang Rodriguez Medical Center, Marikina, PHILIPPINES

P1-IS-104

P1-IS-105

2007 JGOC 25-104 COMPARISON OF MAJOR COMPLICATION RATES AMONG LAVH, LH, AND TLH
Song Moon Park, Ji Eun Lee, Hak Moo Lee, Mi Jung Kim, Sun Young Lee, Sun Young Kim, Kyu Won Lee
Department of Obstetrics and Gynecology, College of Medicine, Korea University, Seoul, Korea

Case:

- 56-year-old
- GSPS (5003)
- Menopause 6 yrs
- Irreducible mass

Physical Exam

Dilemma:

- Grotesquely distorted anatomy
- Huge size of everted vagina
- Anticipated difficult vaginal reconstruction

Surgical* Management:

1. Vaginal hysterectomy
2. Vaginal suspension
3. Vaginal reconstruction

Vaginal Hysterectomy

- Hysterectomy not as important as the repair
- Useful as a means of mobilizing parametrial tissues for use in the reconstructive surgery

Vaginal Suspension: Sacrospinous Ligament Suspension

Vaginal Reconstruction:

- Custom of large vagina should be reduced, but total size should be maintained to avoid intercourse difficulties or even impotence.
- Avoid overzealous reduction of vagina by serial cutting of a broad portion of base of a vagina

Conclusion:

Table 2. Intra- and postoperative variables

	LAVH (n=10)	LH (n=10)	TLH (n=10)
Operating time (min)	123.0±18.0	123.0±18.0	123.0±18.0
Blood loss (ml)	233.0±10.0	233.0±10.0	233.0±10.0
Operative site	233.0±10.0	233.0±10.0	233.0±10.0
Operative time (min)	123.0±18.0	123.0±18.0	123.0±18.0
Blood loss (ml)	233.0±10.0	233.0±10.0	233.0±10.0
Operative site	233.0±10.0	233.0±10.0	233.0±10.0

PARTS OF A SCIENTIFIC POSTER -1

- **Title** page, telling others the title of the project, the people involved in the work and their affiliation.
- **Summary** of the project stating what you have set out to do, how you have done it, the key findings and the main results.
- **Introduction** that should include clear statements about the problem that you are trying to solve, the characteristics that you are trying to discover or the proofs that you are trying to establish. These should then lead to declarations of project aims and objectives.

PARTS OF A SCIENTIFIC POSTER -2

- **Theory** or **Methodology** section that explains the basis of the technique that you are using or the procedure that you have adopted in your study. You should also state and justify any assumptions, so that your results could be viewed in the proper context.
- **Results** section that you use to show illustrative examples of the main results of the work..

PARTS OF A SCIENTIFIC POSTER -3

- **Conclusion** section, listing the main findings of your investigation, and
- **Further Work** section that should contain your recommendations and thoughts about how the work could be progressed; other tests that could be applied, etc.

THE POSTER

- So, before you rush away to put pen to paper or fingers to keyboard, spend a few moments or even hours to **plan** your presentation.
- Unlike oral presentations, where some skilled or experienced speakers may be able to divert attention from a poorly planned presentation, with posters, poor planning is there for all to see.



Guide Questions for Posters

- What is the objective of the investigation?
- Has someone done the work before?
- How have I gone about with the study?
- Why did I follow this particular route of investigation?
- What are the principles governing the technique that I am using?

Guide Questions for Posters

- What assumptions did I make and what were my justifications?
- What problems did I encounter?
- What results did I obtain?
- Have I solved the problem?
- What have I found out?
- Are the analyses sound?

Presenting the Content

□ **Keep the material simple**

- Make full use of the space, but do not cramp a page full of information as the result can often appear messy
- Be concise and do not waffle. Use only pertinent information to convey your message
- Be selective when showing results. Present only those that illustrate the main findings of the project. However, do keep other results handy so that you may refer to them when asked

Presentation Format

□ Use colors sparingly and with taste

- Colors should be used only to emphasise, differentiate and to add interest. Do not use colors just to impress!
- Try to avoid using large swathes of bright garish colors like **bright green**, **pink**, **orange** or **lilac**. Yuck!!
- Pastel shades convey feelings of serenity and calm while dark bright colors conjure images of conflict and disharmony.
- Choose background and foreground color combinations that have high contrast and complement each other - **black or dark blue on white or very light grey is good.**

Presentation Format

□ **Use colors sparingly and with taste**

- It is better to keep the background light as people are used to it (for example newspapers and books)
- If you insist on having a dark background, use colored paper so that you would not have to spray white paper with ink. Not only is this cheaper, you would also not face the problem of a soaked and distorted page.
- Avoid the use of gradient fills. They may look great on a computer display, but unless you have access to a high resolution printer, the paper version can look really tatty.

POSTER COLORS

□ The choice of a background color is up to you. However, softer colors (pastels & greys) may work best as a background - they are easiest to view for hours at a time, and offer the best contrast for text, graphic, and photographic elements.



Blue on Red appears blurry to the human eye.

Yellow on white is hard to read

Red on Blue appears blurry to the human eye.

Font Guidelines

□ Do not use more than 2 font types

- Too many font types distracts, especially when they appear on the same sentence
- Fonts that are easy on the eyes are Times-Roman and Arial.

This is Times-Roman

This is **Arial**

FONT CASE

- **Titles** and **headings** should appear larger than other text, but not too large. The text should also be legible from a distance, say from 1.5m to 2m.
- **Do not use all UPPER CASE type in your posters.** It can make the material difficult to read. Just compare the two sentences below:

WHAT DO YOU THINK OF THIS LINE WHERE ALL THE CHARACTERS ARE IN UPPER CASE?

What do you think of this line, where only the first character of the first word is in upper case?

POSTER STYLES

□ **Maintain a consistent style**

- Inconsistent styles give the impression of disharmony and can interrupt the fluency and flow of your messages.
- Headings on the different pages of the poster should appear in the same position on all pages.
- Graphs should be of the same size and scale especially if they are to be compared.
- If bold lettering is used for emphasis on one page, then do not use italics on others.
- Captions for graphs, drawings and tables should either be positioned at the top or at the bottom of the figure.

POSTER LAYOUT

- **Arrangement of poster components should appear smooth**
 - Preparing sections of the poster on A4 sized paper before sticking them onto mounting boards or display stands.
 - Remember that you are using posters to tell a story about what you have done and achieved. As in report writing, the way you arrange the sections should follow the 'storyline'.
 - Sometimes it is helpful if you provide cutouts of arrows to direct attention to the sequence of the presentation
 - Use a new page/sheet to start off a new section

XX My name
My place

substance X induces Y-cells

Context:

Y-cells require induction
substance X may be
the inducer because:
we know virtually
nothing about X,
but we had some
on the shelf.

lots and lots
lots of tiny
and lots and
more detail
tiny type
tiny tiny



a of tiny type, lot of type
tiny, tiny type, lots and
d lots of tiny type. Detail
is and lots of details, more
and more details. Lots of



lots and lots o
lots of tiny, tiny
and lots and lots
more details an
tiny type and
tiny tiny tin
lot of type



lots and lo
Details a
tails, more
Lots of

if tiny type, lot of type
tiny type, lots and lots
of tiny type. Details and
d lots of details, more
more details. Lots of
a type. Lots of type.

lots of details,
re details. Lots
e. Lots of type.



my type, lot of type
tiny type, lots and lots
of tiny type. Details and



lots and lots of tiny type, lot
lots of tiny, tiny, tiny type, lo
and lots and lots of tiny type

of type
is and lots
Details and



lots and lots of ti
lots of tiny, tiny,
and lots and lots
more details and
tiny type and me
tiny tiny tiny ty

t of type
ots and lots
e. Details and
sils, more
Lots of



more details and lots of th
tiny type and more details
tiny tiny tiny type. Lots of



my type, lot of type
my type, lots and lots
tiny type. Details and
ots of details, more
re details. Lots of
pe. Lots of type.

if lots of tiny type, lo
tiny, tiny, tiny type, l
i and lots of tiny typ
tails and lots of det
is and more details. l


a and lots of tiny typ
of tiny, tiny, tiny typ
is and lots of tiny ty
re details and lots of
ry type and more det
tiny tiny tiny type. L-

lots and lots of ti
lots of tiny, tiny, ti
and lots and lots of
more details and l
tiny type and me
tiny tiny tiny ty



POSTER LAYOUT

- Place the elements of the poster in position:
- The title will appear across the top.
- A brief introduction will appear at the upper left.
- The conclusions will appear at the lower right.
- Methods and Results will fill the remaining space.




The Title

- ❑ This part of the poster includes the title of the work, the authors names, & the institutional affiliations. Think BIG!
- ❑ The title should be readable from 15 - 20 feet away.
- ❑ If space permits, use first names for authors to facilitate interactions.
- ❑ Middle initials and titles are seldom necessary.
- ❑ Use abbreviations where possible.


Poster Text

- Double-space all text,
- -using left-justification;
- - text with even left sides and jagged right sides is easiest to read.
- The text should be large enough to be read easily from at least 6 feet away.



Poster Text

- For section headings (e.g., Introduction), use boldface, maybe about 36-42 point. For supporting text (e.g., text within each section & figure captions), use about 24-28 point (boldface, if appropriate).
- In general, use font sizes proportional to importance:
- largest type - Title
- next largest type - Section headings
- medium type - Supporting material
- smallest type - Details




SEQUENCING


- A poster should use photos, figures, and tables to tell the story of the study. For clarity, present the information in a sequence that is easy to follow:
- Determine a logical sequence for the material you will be presenting.
- Organize that material into sections, e.g., Introduction, Methods, Results, Discussion, Conclusions, & if necessary, Literature Cited. (Avoid using too many citations. If only a few are used, a literature cited section is unnecessary. Instead, cite as follows in the text: Clinton, B. 1993. Auk 107:234-246.).

SEQUENCING

- You may wish to use numbers to help sequence sections of the poster.
- Arrange the material into columns.
- The poster should not rely upon your verbal explanation to link together the various portions.



TOO MUCH TEXT!!!



TOO MUCH INFORMATION !!!

EFFECTS OF METFORMIN ON INSULIN RESISTANCE AND CENTRAL ADIPOSITY IN PATIENTS RECEIVING EFFECTIVE PROTEASOM INHIBITOR (PI) THERAPY

Oliver WITTMANN¹, Barbara WITTMANN²

¹Department of Internal Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
²Charité - Universitätsmedizin Berlin, Berlin, Germany

Background: Metformin is a well-established treatment for insulin resistance and type 2 diabetes mellitus. It is also known to reduce central adiposity. However, the effects of metformin on insulin resistance and central adiposity in patients receiving effective proteasome inhibitor (PI) therapy are not well defined.

Methods: We conducted a prospective, randomized, controlled trial in 20 patients receiving effective PI therapy. The patients were randomized to receive either metformin (n=10) or placebo (n=10) for 12 weeks. The primary endpoint was the change in insulin resistance, measured by the homeostasis model assessment (HOMA-IR). Secondary endpoints included changes in central adiposity, measured by waist circumference and visceral adipose tissue (VAT) area.

Results: The metformin group showed a significant reduction in HOMA-IR compared to the placebo group (p<0.05). Additionally, the metformin group showed a significant reduction in waist circumference and VAT area compared to the placebo group (p<0.05).

Conclusion: Metformin treatment significantly reduces insulin resistance and central adiposity in patients receiving effective PI therapy.



Table 1: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12




Table 2: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Background: Metformin is a well-established treatment for insulin resistance and type 2 diabetes mellitus. It is also known to reduce central adiposity. However, the effects of metformin on insulin resistance and central adiposity in patients receiving effective proteasome inhibitor (PI) therapy are not well defined.

Methods: We conducted a prospective, randomized, controlled trial in 20 patients receiving effective PI therapy. The patients were randomized to receive either metformin (n=10) or placebo (n=10) for 12 weeks. The primary endpoint was the change in insulin resistance, measured by the homeostasis model assessment (HOMA-IR). Secondary endpoints included changes in central adiposity, measured by waist circumference and visceral adipose tissue (VAT) area.

Results: The metformin group showed a significant reduction in HOMA-IR compared to the placebo group (p<0.05). Additionally, the metformin group showed a significant reduction in waist circumference and VAT area compared to the placebo group (p<0.05).

Conclusion: Metformin treatment significantly reduces insulin resistance and central adiposity in patients receiving effective PI therapy.

Table 1: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 2: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 3: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 4: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 5: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 6: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 7: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 8: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 9: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Table 10: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12






Table 11: Mean values and changes from baseline

Parameter	Metformin (n=10)	Placebo (n=10)
HOMA-IR	1.8 ± 0.2	2.5 ± 0.3
Waist circumference (cm)	102 ± 5	108 ± 6
VAT area (cm²)	120 ± 10	140 ± 12

Text should support graphics.

XX My name
My place


substance X induces Y-cells

<h3>Context</h3> <p>Y-cells require induction. X-substance may be the inducer because:</p> <p>We know virtually nothing about X but have it on the shelf</p>	<h3>2 X is expressed in Y-cells only</h3>  <p>text visible at 4 feet away that emphasizes the main point of the figures</p>	<h3>4 Anti-X alters Y transcription</h3>  <p>text visible at 4 feet away that emphasizes the main point of the figures</p>	<h3>6 Summary</h3> <p>X: - is expressed in Y cells - induces Y expression - induces Y transcription factor</p>
<h3>1 We created X-deficient mice</h3>  <p>we've been kind of slow to have around, particularly and over. Cite.</p>	<h3>3 Anti-X inhibits Y cell origin</h3>  <p>text visible at 4 feet away that emphasizes the main point of the figures</p>	<h3>5 Y-cells need Y-transcription</h3>  <p>at attention.</p> <p>text visible at 4 feet away that emphasizes the main point of the figures</p>	<h3>Conclusions</h3> <p>X induces Y cells by inducing the Y transcription factor</p> <p>We Acknowledge NIH grant # XXX</p>

lots of
key type
lots of
key type
lots of
key type

Discard details

Look critically at the layout. Some poster 'experts' suggest that if there is about 20-25% text, 40-45% graphics and 30-40% empty space, you are doing well.



Tiny figures

Even spacing throughout

Type all the same size: tiny

No headings

POSTER GUIDELINES

- **Use active voice** when writing the text.
- Delete all redundant references and filler phrases (such as see Figure 1).
- An abstract may not be necessary. If you've kept the amount of text on your poster to a minimum, an abstract is likely redundant.

The poster is not a publication of record, so excessive detail about methods, or vast tables of data are not necessary. Such material can be discussed with interested persons individually during or after the session, or presented in a handout.

POSTER GUIDELINES

- ❑ **FOR GRAPHS AND ILLUSTRATIONS:**
- ❑ **Show no mercy when editing visual materials!**
- ❑ Use short sentences, simple words, and bullets to illustrate discrete points.
- ❑ Remove all non-essential information from graphs and tables.
- ❑ **If possible, label data lines in graphs directly**, using large type & color.

PRESENTING YOUR POSTER

- Design the poster to address one central question. State the question clearly in the poster, then use your discussion time with individuals to expand or expound upon issues surrounding that central theme.
- Provide an explicit take-home message.
- Summarize implications and conclusions briefly, and in user-friendly language.
- Give credit where it is due. Have an acknowledgments section, in smaller size type (14 - 18 point), where you acknowledge contributors and funding organizations.
- Vary the size and spacing of the poster sections to add visual interest, but do so in moderation.
- Do not wander too far away from your poster during the session; be available for discussion!




Communicating Research Results

- Mario R. Festin MD, MS, MHPed, FPOGS, FPCS
- College of Medicine – Philippine General Hospital
- University of the Philippines Manila



CHOOSING THE JOURNAL TO PRESENT YOUR PAPER

http://www.isinet.com



The screenshot shows a web browser window displaying the Thomson Scientific website. The browser's address bar shows the URL http://www.isinet.com. The website's navigation bar includes links for HOME, ABOUT US, PRESS ROOM, CAREERS, CONTACT US, and THOMSON.COM. Below the navigation bar is the Thomson logo and a search box with a 'GO' button and a link to 'Advanced Search'. A green banner below the search box lists various product categories: Citation Products, Current Awareness Products, Specialized Content, Evaluation/Analytical Tools, Custom Information Services, and Document Delivery. The main content area is divided into three columns. The left column contains a 'Find solutions for:' section with a list of categories: ACADEMIC, GOVERNMENT, NON-PROFIT, CORPORATE, PRODUCTS, CUSTOMER NEWS CENTER, and CONFERENCES AND EVENTS. Below this is a 'REGIONS' section with a dropdown menu set to 'Business Websites' and a 'GO' button. The middle column features a 'WELCOME to THOMSON SCIENTIFIC' header, followed by 'Featured Product' and the 'ISI Web of Knowledge' logo. The text below the logo reads: 'We < Deliver > UNMATCHED QUALITY'. The main headline for the featured product is 'ISI Web of KnowledgeSM - A fully integrated research platform... empowering researchers and accelerating discovery'. Below this is a 'Challenge' section describing FECYT (Fundacion Espanola para la Ciencia y la Tecnologia) and its goals, and a 'Solution' section describing Thomson's partnership with FECYT. The right column contains a 'Highlight' section with a blue background and white text: 'BEAT THE HEAT | Patent & trademark file histories in just hours and a chance at 50 cool gifts >>'. Below this is a 'Browse our little book' section with a white background and black text: 'the <little> book of <BIG> VALUE | ISI Web of KnowledgeSM | More than just a'. At the bottom of the page, there is a 'Press Room' link and a 'View All >' link.

Journal Selection Criteria of ISI

- The evaluation process consists of evaluation of many criteria such as, **Basic Journal Publishing Standards** (including Timeliness of publication, a adherence to International Editorial Conventions, **English Language Bibliographic Information** (including English article titles, keywords, author abstracts, and cited references.)
- ISI also examines the journal's **Editorial Content, the International Diversity of it authors and editors**. Citation Analysis using ISI data is applied to determine the journal's citation history and/or the citation history of its authors and editors.

Do you wish to submit a journal for evaluation?

- ❑ ISI needs at **least three consecutive current issues** to complete an evaluation.
- ❑ Please send the most current issue of the journal, and then each subsequent issues as soon as each is published to the following address:
- ❑ Publication Processing Department
ISI
3501 Market Street
Philadelphia, PA 19104
USA

How do you know if a journal is an ISI journal?

<http://www.isinet.com/cgi-bin/jrnlst/jloptions.cgi?PC=C>

The screenshot shows a web browser window displaying the Thomson ISI website. The browser's address bar contains the URL <http://www.isinet.com/cgi-bin/jrnlst/jloptions.cgi?PC=C>. The website's navigation bar includes links for HOME, ABOUT US, PRESS ROOM, CAREERS, CONTACT US, and THOMSON.COM. The main content area is titled "CC/CLINICAL MEDICINE JOURNAL LIST OPTIONS" and features four primary options:

SEARCH	Find a specific journal by title, title words, or ISSN
VIEW JOURNAL LIST	View a list of all journals
VIEW SUBJECT CATEGORY	View a list of all journals covered in a specific category
VIEW JOURNAL CHANGES	View a list of all journal coverage changes

On the left side of the page, there is a sidebar with various navigation categories:

- Find solutions for:
 - ACADEMIC
 - GOVERNMENT
 - NON-PROFIT
 - CORPORATE
- PRODUCTS
 - CUSTOMER NEWS CENTER
 - CONFERENCES AND EVENTS
- CUSTOMER SUPPORT CENTER
 - RESEARCH SERVICES
 - JOURNAL LISTS**
 - JOURNAL SELECTION PROCESS
 - ISI LINKS
 - ISI ESSAYS
 - HOT RESEARCH
- REGIONS

At the bottom of the sidebar, there is a dropdown menu for "Business Websites" and a "GO" button. The browser's status bar at the bottom shows "Done" and "Internet".



[Advanced Search](#)

Citation Products | Current Awareness Products | Specialized Content | Evaluation/Analytical Tools | Custom Information Services | Document Delivery

Find solutions for:

- ACADEMIC
- GOVERNMENT
- NON-PROFIT
- CORPORATE

- PRODUCTS
- CUSTOMER NEWS CENTER
- CONFERENCES AND EVENTS

- CUSTOMER SUPPORT CENTER
- RESEARCH SERVICES
- JOURNAL LISTS**
- JOURNAL SELECTION PROCESS
- ISI LINKS
- ISI ESSAYS
- HOT RESEARCH

REGIONS

CC/CLINICAL MEDICINE JOURNAL SEARCH

Search by:	Type search term:
<input type="text" value="Title Word"/> <input type="button" value="v"/>	<i>Enter a title word, full title, or ISSN (see search examples below)</i> <input type="text" value="obstetrics"/>
<input type="button" value="SEARCH"/>	
Title Word:	<i>Enter as CELL or CELL*</i>
Full Journal Title:	<i>Enter as JOURNAL OF CELL TRANSPLANTATION or JOURNAL OF CEL</i>
ISSN:	<i>Enter as 1234-5678</i>

Standard International Journals

- ❑ New England Journal of Medicine
- ❑ Lancet
- ❑ Bulletin of the WHO
- ❑ Annals of Internal Medicine
- ❑ Contraception

- ❑ NO PHILIPPINE MEDICAL JOURNAL IN THE ISI


MEDLINE PUBMED

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed>

The screenshot shows the PubMed website interface within a browser window. The browser's address bar contains the URL <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed>. The browser's toolbar includes navigation buttons (back, forward, stop, refresh), a search icon, a star icon, a globe icon, an envelope icon, a printer icon, a document icon, a folder icon, and a user icon. The website header features the NCBI logo on the left, the PubMed logo in the center, and the National Library of Medicine (NLM) logo on the right. A "My NCBI" button with "Sign In" and "Register" links is located in the top right corner. Below the header is a navigation bar with tabs for "All Databases", "PubMed", "Nucleotide", "Protein", "Genome", "Structure", "OMIM", "PMC", "Journals", and "Books". The "PubMed" tab is selected. A search bar is present with a dropdown menu set to "PubMed" and a "for" field. "Go" and "Clear" buttons are next to the search bar. Below the search bar are tabs for "Limits", "Preview/Index", "History", "Clipboard", and "Details". The main content area contains a list of search tips:

- To get started, enter one or more search terms.
- Search terms may be [topics](#), [authors](#) or [journals](#).

A prominent yellow-bordered box highlights a promotional message:

 **Set up an automated PubMed update in less than 5 minutes.**

(1) Get a [My NCBI account](#). (2) Save your search.
(3) Your PubMed updates can be e-mailed directly to you.

Read the [My NCBI Help](#) material to explore other options, such as automated updates of other databases, setting search filters, and highlighting search terms.

PubMed is a service of the [National Library of Medicine](#) that includes over 15 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.


At the bottom of the page, there is a banner for the "New Global NCBI Search Engine".



The left sidebar contains navigation links:

- About Entrez
- Text Version
- Entrez PubMed
 - Overview
 - Help | FAQ
 - Tutorial
 - New/Noteworthy
 - E-Utilities
- PubMed Services
 - Journals Database
 - MeSH Database
 - Single Citation Matcher
 - Batch Citation Matcher
 - Clinical Queries
 - Special Queries
 - LinkOut
 - My NCBI (Cubby)
- Related Resources

NATIONAL CENTER FOR BIOMEDICAL INFORMATION

<http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi?itool=frompm>























  *Entrez, The Life Sciences Search Engine.*

HOME SEARCH SITE MAP PubMed All Databases Human Genome GenBank Map Viewer BLAST

Search across databases Help

Welcome to the Entrez cross-database search page

 PubMed: biomedical literature citations and abstracts ?	 Books: online books ?
 PubMed Central: free, full text journal articles ?	 OMIM: online Mendelian Inheritance in Man ?
 Site Search: NCBI web and FTP sites ?	 OMIA: online Mendelian Inheritance in Animals ?
 Nucleotide: sequence database (GenBank) ?	 UniGene: gene-oriented clusters of transcript sequences ?
 Protein: sequence database ?	 CDD: conserved protein domain database ?
 Genome: whole genome sequences ?	 3D Domains: domains from Entrez Structure ?
 Structure: three-dimensional macromolecular structures ?	 UniSTS: markers and mapping data ?
 Taxonomy: organisms in GenBank ?	 PopSet: population study data sets ?
 SNP: single nucleotide polymorphism ?	 GEO Profiles: expression and molecular abundance profiles ?
 Gene: gene-centered information ?	 GEO DataSets: experimental sets of GEO data ?

NATIONAL CENTER FOR BIOMEDICAL INFORMATION

<http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi?itool=frompm>

The screenshot displays the PubMed web interface. At the top, the NCBI logo is on the left, and the PubMed logo is in the center. To the right of the PubMed logo is the National Library of Medicine (NLM) logo. A navigation bar contains tabs for 'All Databases', 'PubMed', 'Nucleotide', 'Protein', 'Genome', 'Structure', 'OMIM', 'PMC', 'Journals', and 'Books'. Below this is a search bar with 'PubMed' selected in the dropdown and 'Festin M' entered. Buttons for 'Go', 'Clear', and 'Save Search' are visible. Below the search bar are tabs for 'Limits', 'Preview/Index', 'History', 'Clipboard', and 'Details'. The 'Display' section shows 'Summary' selected, 'Show 20' items, and 'Sort by' options. A summary bar indicates 'All: 12' items and 'Review: 1'. The main content area shows 'Items 1 - 12 of 12' and 'One page.' Three search results are visible, each with a checkbox, a list icon, a title, authors, journal information, and PMID. The first result is for a review article on perinatal and reproductive health. The second is for a study on group B streptococcal colonization in pregnant women. The third is for a study on the performance of an optical immunoassay test for group B streptococcus. The fourth result is partially visible at the bottom.

NCBI

PubMed

National Library of Medicine NLM

My NCBI
[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Festin M Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to

All: 12 Review: 1

Items 1 - 12 of 12 One page.

1: [Whitney CG, Daly S, Limpongsanurak S, Festin MR, Thinn KK, Chipato T, Lumbiganon P, Sauvarin J, Andrews W, Tolosa JE: Global Network For Perinatal And Reproductive Health.](#) Related Articles, Links

2: [Thinkhamrop J, Limpongsanurak S, Festin MR, Daly S, Schuchat A, Lumbiganon P, Zell E, Chipato T, Win AA, Perilla MJ, Tolosa JE, Whitney CG.](#) Related Articles, Links

3: [Ngelangel CA, Limson GM, Cordero CP, Abelardo AD, Avila JM, Festin MR: UP-DOH CCSHOSG.](#) Related Articles, Links

Acetic-acid guided visual inspection vs. cytology-based screening for cervical cancer in the

International Council of Medical Journal Editors <http://www.icmje.org/>



ICMJE

International Committee of Medical Journal Editors

Uniform Requirements for Manuscripts

Statement of Purpose
Ethical Considerations
Publishing and Editorial Issues
Manuscript Preparation
References

Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication

Updated October 2004

The following information is available to be viewed/printed in [Adobe Acrobat pdf format](#).

About the ICMJE

Authors
Use and Distribution
Inquiries

URM Journals List

ICMJE Editorials

May 2005 Update on Trials Registration
2004 Update on Trials Registration
Clinical Trial Registration
Sponsorship, Authorship, and Accountability

International Committee of Medical Journal Editors

I. Statement of Purpose

- A. [About](#) the Uniform Requirements
- B. [Potential Users](#) of the Uniform Requirements
- C. [How to Use](#) the Uniform Requirements

II. Ethical Considerations in the Conduct and

Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication

Updated October 2004

International Committee of Medical Journal Editors

- I. Statement of Purpose
 - A. About the Uniform Requirements
 - B. Potential Users of the Uniform Requirements
 - C. How to Use the Uniform Requirements
 - II. Ethical Considerations in the Conduct and Reporting of Research
 - A. Authorship and Contributorship
 - 1. Byline Authorship
 - 2. Contributors Listed in Acknowledgements
 - B. Editorship
 - 1. The Role of the Editor
 - 2. Editorial Freedom
 - C. Peer Review
 - D. Conflicts of Interest
 - 1. Potential Conflicts of Interest Related to Individual Authors' Commitments
 - 2. Potential Conflicts of Interest Related to Project Support
 - 3. Potential Conflicts of Interest Related to Commitments of Editors, Journal Staff, or Reviewers
 - E. Privacy and Confidentiality
 - 1. Patients and Study Participants
 - 2. Authors and Reviewers
 - F. Protection of Human Subjects and Animals in Research
 - III. Publishing and Editorial Issues Related to Publication in Biomedical Journals
 - A. Obligation to Publish Negative Studies
 - B. Corrections, Retractions, and "Expressions of Concern"
 - C. Copyright
 - D. Overlapping Publications
 - 1. Duplicate Submission
 - 2. Redundant Publication
 - 3. Acceptable Secondary Publication
 - 4. Competing Manuscripts based on the Same Study
 - a. Differences in Analysis or Interpretation
 - b. Differences in Reported Methods or Results
 - 5. Competing Manuscripts Based on the Same Database
 - E. Correspondence
 - F. Supplements, Theme Issues, and Special Series
 - G. Electronic Publishing
 - H. Advertising
 - 1. Medical Journals and the General Media
 - J. Obligation to Register Clinical Trials
 - IV. Manuscript Preparation and Submission
 - A. Preparing a Manuscript for Submission to Biomedical Journals
 - 1. General Principles and Reporting Guidelines
 - a. General Principles
 - b. Reporting Guidelines for Specific Study Designs
 - 2. Title page
 - 3. Conflict of Interest Notification Page
 - 4. Abstract and Key Words
 - 5. Introduction
 - 6. Methods
 - a. Selection and Description of Participants
 - b. Technical Information
 - c. Statistics
 - 7. Results
 - 8. Discussion
 - 9. References
 - a. General Considerations Related to References
 - b. Reference Style and Format
 - 10. Tables
 - 11. Illustrations (Figures)
 - 12. Legends for Illustrations (Figures)
 - 13. Units of Measurement
 - 14. Abbreviations and Symbols
 - B. Sending the Manuscript to the Journal
 - V. References
 - A. Print References Cited in this Document
 - B. Other Sources of Information Related to Biomedical Journals
 - VI. About the International Committee of Medical Journal Editors
 - VII. Authors of the Uniform Requirements
 - VIII. Use, Distribution, and Translation of the Uniform Requirements
 - IX. Inquiries
- I. STATEMENT OF PURPOSE
 - IA. About the Uniform Requirements

A small group of editors of general medical journals met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the National Library of Medicine, were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors

II. ETHICAL CONSIDERATIONS IN THE CONDUCT AND REPORTING OF RESEARCH

II.A Authorship and Contributorship

II.A.1. *Byline Authors*

An “author” is generally considered to be someone who has made substantive intellectual contributions to a published study, and biomedical authorship continues to have important academic, social, and financial implications. (1) In the past, readers were rarely provided with information about contributions to studies from those listed as authors and in acknowledgments. (2) Some journals now request and publish information about the contributions of each person named as having participated in a submitted study, at least for original research. Editors are strongly encouraged to develop and implement a contributorship policy, as well as a policy on identifying who is responsible for the integrity of the work as a whole.

While contributorship and guarantorship policies obviously remove much of the ambiguity surrounding contributions, it leaves unresolved the question of the quantity and quality of contribution that qualify for authorship. The International Committee of Medical Journal Editors has recommended the following criteria for authorship; these criteria are still appropriate for those journals that distinguish authors from other contributors.

Guidelines for Authors

- Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.
- When a large, multi-center group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript (3). These individuals should fully meet the criteria for authorship defined above and editors will ask these individuals to complete journal-specific author and conflict of interest disclosure forms. When submitting a group author manuscript, the corresponding author should clearly indicate the preferred citation and should clearly identify all individual authors as well as the group

name. Journals will generally list other members of the group in the acknowledgements. The National Library of Medicine indexes the group name and the names of individuals the group has identified as being directly responsible for the manuscript.

- Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship.
- All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.



WHO International Clinical Trials Registry Platform

- a new requirement for international publication

Technical Consultation on Trial Registration Standards

25-27 April 2005

Geneva, World Health Organization

Status of Publication of Clinical Trials

□ What are usually published are clinical trials that :

- Confirm or show new, positive, innovative, or important findings.
- Come with large sample sizes or with many centers.
- Are written by famous personalities or from well established institutions.
- Come from well-supported agencies

Problem of **Publication Bias**

- Journals do not publish:
 - Repeats of already established studies
 - Studies which contradict or do not support present beliefs
 - Studies with small sample sizes which do not have good power or levels of significance
 - Studies from obscure institutions or unknown personalities
- Other papers do not reach regular journals

ICMJE

□ International Council of Medical Journal Editors

Catherine D. De Angelis, M.D., M.P.H.
Editor-in-Chief, *JAMA*

Jeffrey M. Drazen, M.D.
Editor-in-Chief, *New England Journal of Medicine*

Prof. Frank A. Frizelle, M.B., Ch.B., M.Med.S
F.R.A.C.S.

Editor, *The New Zealand Medical Journal*

Charlotte Haug, M.D., Ph.D., M.Sc.
Editor-in-Chief, *Norwegian Medical Journal*

John Hoey, M.D.
Editor, *CMAJ*

Richard Horton, F.R.C.P.
Editor, *The Lancet*

Sheldon Kotzin, M.L.S.
Executive Editor, MEDLINE
National Library of Medicine

Christine Laine, M.D., M.P.H.
Senior Deputy Editor, *Annals of Internal Medicine*

Ana Marusic, M.D., Ph.D.
Editor, *Croatian Medical Journal*

A. John P.M. Overbeke, M.D., Ph.D.
Executive Editor, *Nederlands Tijdschrift voor Geneeskunde*
(*Dutch Journal of Medicine*)

Torben V. Schroeder, M.D., D.M.Sc.
Editor, *Journal of the Danish Medical Association*

Harold C. Sox, M.D.
Editor, *Annals of Internal Medicine*

Martin B. Van Der Weyden, M.D.
Editor, *The Medical Journal of Australia*

Copyright © 2005 Massachusetts Medical Society.

Requirement of Trial Registration

- The ICMJE wants to **ensure public access to all “clinically directive” trials** — trials that test a clinical hypothesis about health outcomes (e.g., “Is drug X as effective as drug Y in treating heart failure?”).
- The ICMJE think the public deserves to know about trials that could shape the body of evidence about clinical effectiveness or adverse effects
- The ICMJE require registration of all trials whose primary purpose is to affect clinical practice (phase 3 trials).

Why register?

- ❑ Obligation to participants, the public
- ❑ Address analysis, reporting and publication biases
- ❑ Contribute to systematic reviews
- ❑ Speed access to results
- ❑ Increase effectiveness of research funding
- ❑ Increase participation by patients, doctors, researchers

Registers exist but,

- ❑ Designed for different purposes
- ❑ Compliance is low
- ❑ Field fragmented
- ❑ Even systematic reviewers do not/cannot use them
- ❑ Awareness is low
- ❑ It is not easy to search for all relevant trials

THE NEW ENGLAND JOURNAL OF MEDICINE

EDITORIALS



Is This Clinical Trial Fully Registered? — A Statement from the International Committee of Medical Journal Editors

In September 2004, the members of the International Committee of Medical Journal Editors (ICMJE) published a joint editorial aimed at promoting registration of all clinical trials.¹ We stated that we will consider a trial for publication only if it has been registered before the enrollment of the first patient. This policy applies to trials that start enrolling on or after July 1, 2005. Because many ongoing trials were not registered at inception, we will consider for publication ongoing trials that are registered before September 13, 2005. Our goal then and now is to foster a comprehensive, publicly available database of clinical trials. A complete registry of trials would be a fitting way to thank the thousands of participants who have placed themselves at risk by volunteering for clinical trials. They deserve to know that the information that accrues from their altruism is part of the public record, where it is available to guide decisions about patient care, and deserve to know that decisions about their care rest on all of the evidence, not just the trials that authors decided to report and that journal editors decided to publish.

We are not alone in pursuing this goal. The World Health Organization (WHO), through meet-

ings, trial authors and sponsors want to be sure that they understand our requirements, so that reports of their research will be eligible for editorial review. The purpose of this joint and simultaneously published editorial is to answer questions about the ICMJE initiative and to bring our position into harmony with that of others who are working toward the same end.

Our definition of a clinical trial remains essentially the same as in our September 2004 editorial: "Any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome." By "medical intervention" we mean any intervention used to modify a health outcome. This definition includes drugs, surgical procedures, devices, behavior treatments, process-of-care changes, and the like. We update our 2004 editorial to state that a trial must have at least one prospectively assigned treatment control or comparison group in order to trigger the requirement for registration.

Among the trials that meet this definition, which need to be registered? The ICMJE wants to ensure

ICMJE Statement

- The research enterprise has an obligation to conduct research ethically and report it honestly.
- Unfortunately, selective reporting of trials does occur, and it distorts the body of evidence available for clinical decision making.
- When research sponsors or investigators conceal the presence of selected trials, these studies cannot influence the thinking of patients, clinicians, other researchers and experts who write practice guidelines or decide on insurance coverage.

ICMJE Statement

- The ICMJE member journals will require as a condition of consideration for publication, registration in a public trials registry.
- Trials must register at or before the onset of patient enrolment.
- Policy applies to any clinical trial starting enrolment after **July 1, 2005**, and for trials prior, registration by **September 13, 2005**.

ICMJE Statement

- The registry must be accessible to the public at no charge.
- It must be open to all prospective registrants and managed by a non-for-profit organization.
- There must be a mechanism to ensure the validity of registration data, and the registry should be electronically searchable.
- There is a list of recommended fields.
- www.clinicaltrials.gov – US NLM

ClinicalTrials.gov

A service of the U.S. National Institutes of Health
Developed by the National Library of Medicine



Linking patients to medical research

- [Home](#) | [Search](#) | [Browse](#) | [Resources](#) | [Help](#) | [What's New](#) | [About](#)

ClinicalTrials.gov provides regularly updated information about federally and privately supported clinical research in human volunteers. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and [phone numbers](#) for more details. Before searching, you may want to [learn more](#) about clinical trials.

Search Clinical Trials

Example: heart attack, Los Angeles

Search

[Tips](#)

Search by Specific Information

[Focused Search](#) - search by disease, location, treatment, sponsor...

Browse

- [Browse by Condition](#) - studies listed by disease or condition
- [Browse by Sponsor](#) - studies listed by funding organization
- [Browse by Status](#) - studies listed by recruitment status

Resource Information

[Understanding Clinical Trials](#) - information explaining and describing clinical trials



The National Research Register



- Home
- Search the Register online
- Research results
- Deadlines/release dates
- Data providers' page
- General questions
- Links
- Help
- Contact us

What is the National Research Register?

Description

The National Research Register (NRR) is a database of ongoing and recently completed research projects funded by, or of interest to, the United Kingdom's National Health Service (NHS).

Contributors

About 350 organisations (NHS Trusts, national and regional funding programmes, universities, charities) in England, Scotland and Wales.

Data collection and publication

New records are added and existing records are updated every three months to a growing list of records. The Register provides a

News:

28 January 2005: Issue 1 of 2005 published

This issue contains 129,396 records in the NRR Projects Database collected up to December 2004.

22 October 2004: New issue of NRR published with links to the Research Findings Register (ReFeR)

Links have been added to the research results field in NRR project records allowing you to search the Research Findings Register (ReFeR) for related records. ReFeR (<http://www.refer.nhs.uk>) is a database of the findings of research studies funded by the Department of Health in England. [Search the new issue here](#)

International Federation of Pharmaceutical Manufacturers and Associations

- <http://www.ifpma.org/News/NewsRelatedDetail.aspx?nID=2205>

- *“The industry recognizes that there are important public health benefits, including increased confidence, associated with making clinical trial information more widely available to healthcare practitioners, patients and others”,*
 - said Dr. Harvey E. Bale, Director General of IFPMA.

- Beginning mid 2005, the industry will make the results public of trials that have taken place – whether positive or negative – but also information on those that are just being initiated.

Table 1. Minimal Registration Data Set.*

Item	Comment
1. Unique trial number	The unique trial number will be established by the primary registering entity (the registry).
2. Trial registration date	The date of registration will be established by the primary registering entity.
3. Secondary IDs	May be assigned by sponsors or other interested parties (there may be none).
4. Funding source(s)	Name of the organization(s) that provided funding for the study.
5. Primary sponsor	The main entity responsible for performing the research.
6. Secondary sponsor(s)	The secondary entities, if any, responsible for performing the research.
7. Responsible contact person	Public contact person for the trial, for patients interested in participating.
8. Research contact person	Person to contact for scientific inquiries about the trial.
9. Title of the study	Brief title chosen by the research group (can be omitted if the researchers wish).
10. Official scientific title of the study	This title must include the name of the intervention, the condition being studied, and the outcome (e.g., The International Study of Digoxin and Death from Congestive Heart Failure).

11. Research ethics review	Has the study at the time of registration received appropriate ethics committee approval (yes/no)? (It is assumed that all registered trials will be approved by an ethics board before commencing.)
12. Condition	The medical condition being studied (e.g., asthma, myocardial infarction, depression).
13. Intervention(s)	A description of the study and comparison/control intervention(s). (For a drug or other product registered for public sale anywhere in the world, this is the generic name; for an unregistered drug the generic name or company serial number is acceptable). The duration of the intervention(s) must be specified.
14. Key inclusion and exclusion criteria	Key patient characteristics that determine eligibility for participation in the study.
15. Study type	Database should provide drop-down lists for selection. This would include choices for randomized vs. non-randomized, type of masking (e.g., double-blind, single-blind), type of controls (e.g., placebo, active), and group assignment (e.g., parallel, crossover, factorial).
16. Anticipated trial start date	Estimated enrollment date of the first participant.
17. Target sample size	The total number of subjects the investigators plan to enroll before closing the trial to new participants.
18. Recruitment status	Is this information available (yes/no)? (If yes, link to information.)
19. Primary outcome	The primary outcome that the study was designed to evaluate. Description should include the time at which the outcome is measured (e.g., blood pressure at 12 months).
20. Key secondary outcomes	The secondary outcomes specified in the protocol. Description should include time of measurement (e.g., creatinine clearance at 6 months).

* The data fields were specified at a meeting convened by the WHO in April 2005; the explanatory comments are largely from the ICMJE.

Current status of trial registration and results disclosure

- International partnerships / collaborations can help:
 - To increase understanding of issues
 - To build trust among all parties
 - To facilitate buy-in (for initiatives) from the public, the research community and the governments
- The project was discussed at the WHA May 2005
- WHO role depends on support from the international community
- ICMJE published updated statement in NEJM May 2005

International Clinical Trials Registry Platform (ICTRP)

[WHO](#) > [WHO sites](#) > International Clinical Trials Registry Platform

International Clinical Trials Registry Platform (ICTRP)

Mission statement

The WHO International Clinical Trial Registry Platform (ICTRP) is a global project to facilitate access to information about controlled trials and their results.

Program objectives

- Provide global standards for the registration and disclosure of trials and their results.
- Establish a global network of certified clinical trial registers.
- Establish a state-of-art technical system comprising a one-stop global search function of certified registers, a system of unambiguous trial identification and a template register.
- Propose and advocate for efficient methods of compliance.
- Advise and help build capacity for clinical trial registration.
- Establish an ongoing business model for permanent operation by 2006.

RPC DEPARTMENT

[World Report on Knowledge for Better Health](#)

[Ministerial Summit on Health Research](#)

RHR DEPARTMENT

[Link to the RHR Controlled Trials Register](#)

[UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction \(HRP\)](#)

Publication of Philippine RCTs

The screenshot shows a web browser window displaying a PubMed search results page. The browser's address bar is empty, and the window title is 'Internet'. The page content is as follows:

Limits: Clinical Trial

Display: Summary Show: 50 Sort by: Send to:

All: 26 Review: 0 ✕

Items 1 - 26 of 26 One page.

- 1: [Uy HS, Reyes JM, Flores JD, Lim-Bon-Siong R.](#) Related Articles, Links
Comparison of fibrin glue and sutures for attaching conjunctival autografts after pterygium excision.
Ophthalmology. 2005 Apr;112(4):667-71.
PMID: 15808260 [PubMed - indexed for MEDLINE]
- 2: [Perez AR, Roxas MF, Hilvano SS.](#) Related Articles, Links
A randomized, double-blind, placebo-controlled trial to determine effectiveness of antibiotic prophylaxis for tension-free mesh herniorrhaphy.
J Am Coll Surg. 2005 Mar;200(3):393-7; discussion 397-8.
PMID: 15737849 [PubMed - indexed for MEDLINE]
- 3: [Ngelangel CA, Limson GM, Cordero CP, Abelardo AD, Avila JM, Festin MR; UP-DOH CCSHOSG.](#) Related Articles, Links
Acetic-acid guided visual inspection vs. cytology-based screening for cervical cancer in the Philippines.
Int J Gynaecol Obstet. 2003 Nov;83(2):141-50.
PMID: 14550588 [PubMed - indexed for MEDLINE]
- 4: [Azanza MP.](#) Related Articles, Links
Canned rice products as Philippine military food ration.
Int J Food Sci Nutr. 2003 May;54(3):235-40.
PMID: 12775372 [PubMed - indexed for MEDLINE]

The left sidebar contains the following navigation links:

- About Entrez
- Text Version
- Entrez PubMed
 - Overview
 - Help | FAQ
 - Tutorial
 - New/Noteworthy
 - E-Utilities
- PubMed Services
 - Journals Database
 - MeSH Database
 - Single Citation Matcher
 - Batch Citation Matcher
 - Clinical Queries
 - Special Queries
 - LinkOut
 - My NCBI (Cubby)
- Related Resources
 - Order Documents
 - NLM Catalog
 - NLM Gateway
 - TOXNET
 - Consumer Health
 - Clinical Alerts
 - ClinicalTrials.gov
 - PubMed Central



Scientific Paper Publication in the University of the Philippines

- Mario R. Festin MD, MS, MHPEd, FPOGS, FPCS
- College of Medicine – Philippine General Hospital
- University of the Philippines Manila